The FINANCIAL — GE Healthcare, a division of General Electric Company is showcasing the recently FDA-cleared Vivid E9 cardiovascular ultrasound system at Heart Rhythm 2012, the 33rd Annual Scientific Sessions of the Heart Rhythm Society, taking place this week in Boston.
The Vivid E9 Breakthrough 2012 (BT12) includes a 4D transducer for transesophageal echocardiography (TEE), and also provides innovative tools designed to help improve workflow efficiency through simplified image acquisition, intuitive navigation and advanced quantification.
While Vivid E9 is currently used most frequently in the echo lab, the availability of the 4D TEE transducer enables the system to be used more often in clinical settings including the EP lab, cath lab, and the operating room. According to the General Electric Company, the TEE transducer will allow clinicians to view precise images of the heart during assessment/diagnosis performed in the echo lab, and to support invasive surgical procedures in the operating room, as well as image-guided procedures in the cath and EP lab. With the TEE transducer, Vivid E9 can now be leveraged for procedures including ablation and device implants.
“The product enhancements now available on the Vivid E9 – specifically the 4D TEE transducer and new workflow enhancements – were designed with our customers in the EP lab and other settings in mind,” said Al Lojewski, General Manager of Cardiovascular Ultrasound at GE Healthcare. “We look forward to introducing this new system at HRS and extending its benefits beyond the echo lab into additional settings such as the EP lab, with the goal of making 4D imaging accessible and efficient across the continuum of care in cardiology.”